Home » Medical Microbiology
Tag:

Medical Microbiology

Health

Effective Strategies for Reducing Healthcare-Associated Clostridium difficile Infections and Enhancing Infection Control Measures in Antimicrobial Resistance Contexts

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

  • Akoghlanian G, Lakshmi S. The difficile in clostridium difficile infection. Int J Infect Dis. 2018;77:14–5.

    Article
    PubMed

    Google Scholar

  • Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, et al. SER-109, an oral Microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med. 2022;386(3):220–9.

    Article
    CAS
    PubMed

    Google Scholar

  • Owens RC Jr., Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31.

    Article
    PubMed

    Google Scholar

  • Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308–15.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Vital signs. Preventing clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61(9):157–62.

    Google Scholar

  • Li C, Li Y, Huai Y, Liu S, Meng X, Duan J, Klena JD, Rainey JJ, Wu A, Rao CY. Incidence and outbreak of Healthcare-Onset Healthcare-Associated clostridioides difficile infections among intensive care patients in a large teaching hospital in China. Front Microbiol. 2018;9:566.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Turner NA, Krishnan J, Nelson A, Polage CR, Sinkowitz-Cochran RL, Fike L, Kuhar DT, Kutty PK, Snyder RL, Anderson DJ. CDC’s hospital-Onset clostridioides difficile prevention framework in a regional hospital network. JAMA Netw Open. 2024;7(3):e243846.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Barker AK, Alagoz O, Safdar N. Interventions to reduce the incidence of Hospital-Onset clostridium difficile infection: an Agent-Based modeling approach to evaluate clinical effectiveness in adult acute care hospitals. Clin Infect Dis. 2018;66(8):1192–203.

    Article
    PubMed

    Google Scholar

  • Boyce JM. Hand and environmental hygiene: respective roles for MRSA, multi-resistant gram negatives, clostridioides difficile, and Candida spp. Antimicrob Resist Infect Control. 2024;13(1):110.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Khanafer N, Voirin N, Barbut F, Kujerin E, Vanhems P. Hospital management or clostridium difficile infection: a review of the literature. J Hosp Infect. 2015;90(2):91–101.

    Article
    CAS
    PubMed

    Google Scholar

  • McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. J Hosp Infect. 2018;99(4):443–52.

    Article
    CAS
    PubMed

    Google Scholar

  • You E, Song H, Cho J, Lee J. Reduction in the incidence of hospital-acquired clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use. Int J Infect Dis. 2014;22:9–10.

    Article
    PubMed

    Google Scholar

  • Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001.

    Article
    PubMed

    Google Scholar

  • Barker AND, Number C, Munza JS, Vaughn VM, Safedr N. Reducing clostridium difficile in the inpatient setting: A systematic review of the adherence to and effectiveness of C. Difficult prevention bundles. Infect Control Hosp Epidemiol. 2017;38(6):639–50.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Collins DA, Sohn KM, Wu Y, Ouchi K, Ishii Y, Elliott B, Riley TV, Tateda K. Clostridioides difficile infection in the Asia-Pacific region. Emerg Microbes Infect. 2020;9(1):42–52.

    Article
    CAS
    PubMed

    Google Scholar

  • Khun PA, Riley TV. Epidemiology of clostridium (Clostridioides) difficile infection in Southeast Asia. Am J Trop Med Hyg. 2022;107(3):517–26.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Aldhamy H, Maniatopoulos G, McCune VL, Mansi I, Althaqafy M, Pearce MS. Knowledge, attitude and practice of infection prevention and control precautions among laboratory staff: a mixed-methods systematic review. Antimicrob Resist Infect Control. 2023;12(1):57.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Fabre V, Cosgrove SE, Lessa FC, Patel TS, Reyes-Morales G, Aleman WR, Alvarez AA, Aquiles B, Arauz AB, Arguello F, et al. Knowledge, attitudes and perceptions of Latin American healthcare workers relating to antibiotic stewardship and antibiotic use: a cross-sectional multi-country study. Antimicrob Resist Infect Control. 2024;13(1):47.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Hong E, Mao J, Ke Z, Tao W. Knowledge, attitudes and practices towards community-acquired pneumonia and COVID-19 among general population: a cross-sectional study. Antimicrob Resist Infect Control. 2024;13(1):6.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Lee YC, Wang JT, Chen AC, Sheng WH, Chang SC, Chen YC. Changing incidence and clinical manifestations of clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect. 2012;45(4):287–95.

    Article
    CAS
    PubMed

    Google Scholar

  • Kato H, Senoh M, Honda H, Fukuda T, Tagashira Y, Horiuchi H, Chiba H, Suzuki D, Hosokawa N, Kitazono H, et al. Clostridioides (Clostridium) difficile infection burden in japan: A multicenter prospective study. Anaerobe. 2019;60:102011.

    Article
    PubMed

    Google Scholar

  • Hensgens MP, GOPHHUIS AND, VAN KINDAY CM, CROBACH MJ, HARANUS C, COIJUSE EJSPER. Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis. 2011;30(4):587–93.

    Article
    CAS
    PubMed

    Google Scholar

  • Aguilar RC, Salmanton-García J, Carney J, Böll B, Kochanek M, Jazmati N, Cornely OA, Vehreschild M. Clostridioides difficile infections in the intensive care unit: a monocentric cohort study. Infection. 2020;48(3):421–7.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Dodek PM, Norena M, Ayas NT, Romney M, Wong H. Length of stay and mortality due to clostridium difficile infection acquired in the intensive care unit. J Crit Care. 2013;28(4):335–40.

    Article
    PubMed

    Google Scholar

  • L, Meybeck A, Gois J, Devos P, Patoz P, Bousskey N, Delannoy PY, Chiche A, Georges H, George H, George H, Leroy O. Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors. Infection. 2014;42(1):23–30.

    Article
    CAS
    PubMed

    Google Scholar

  • Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, Campbell H, Kyaw MH, Nair H. Global burden of clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407.

    Article
    PubMed

    Google Scholar

  • Tansarli GS, Falagas ME, Fang FC. Clinical significance of toxin EIA positivity in patients with suspected clostridioides difficile infection: systematic review and meta-analysis. J Clin Microbiol. 2025;63(1):e0097724.

    Article
    PubMed

    Google Scholar

  • Bobo LD, Dubberke is, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest. 2011;140(6):1643–53.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Lee JC, Hung YP, Tsai BY, Tsai PJ, Ko WC. Severe clostridium difficile infections in intensive care units: diverse clinical presentations. J Microbiol Immunol Infect. 2021;54(6):1111–7.

    Article
    CAS
    PubMed

    Google Scholar

  • Jones KA, Onwubiko UN, Kubes J, Albrecht B, Paciullo K, Howard-Anderson J, Suchindran S, Trible R, Jacob JT, Yi SH, et al. Reductions in inpatient fluoroquinolone use and postdischarge clostridioides difficile infection (CDI) from a systemwide antimicrobial stewardship intervention. Antimicrob Steward Healthc Epidemiol. 2021;1(1):e32.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Graber CJ. Behavioral change challenges in limiting fluoroquinolone and extended-spectrum cephalosporins to prevent clostridioides difficile disease. Infect Control Hosp Epidemiol. 2020;41(10):1194–5.

    Article
    PubMed

    Google Scholar

  • Angulo FJ, Ghia C, Fletcher MA, Ozbilgili E, Morales GDC. The burden of clostridioides difficile infections in South-East Asia and the Western pacific: A narrative review. Anaerobe. 2024;86:102821.

    Article
    CAS
    PubMed

    Google Scholar

  • Wen X, Shen C, Xia J, Zhong LL, Wu Z, Ahmed M, Long N, Ma F, Zhang G, Wu W, et al. Whole-Genome sequencing reveals the high nosocomial transmission and antimicrobial resistance of clostridioides difficile in a single center in china, a Four-Year retrospective study. Microbiol Spectr. 2022;10(1):e0132221.

    Article
    PubMed

    Google Scholar

  • Bouza E, Rodriguez- Bel clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience. J Crit Care. 2015;30(3):543–9.

    Article
    CAS
    PubMed

    Google Scholar

  • Wang X, Cai L, Yu R, Huang W, Zong Z. ICU-Onset clostridium difficile infection in a university hospital in china: a prospective cohort study. PLoS ONE. 2014;9(11):e111735.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Zhang X, Wang X, Yang J, Liu X, Cai L, Zong Z. Colonization of toxigenic clostridium difficile among ICU patients: a prospective study. BMC Infect Dis. 2016;16:397.

    Article
    PubMed
    PubMed Central

    Google Scholar

    • How does the increasing prevalence of antimicrobial resistance impact the effectiveness of traditional treatments for *Clostridium difficile* infections?

    Table of Contents

    Effective Strategies for Reducing Healthcare-Associated Clostridium difficile Infections and Enhancing Infection Control Measures in Antimicrobial Resistance Contexts

    Understanding the C. difficile Challenge & Antimicrobial Resistance

    Healthcare-associated clostridium difficile infection (HA-CDI) remains a significant public health concern, notably within the escalating landscape of antimicrobial resistance (AMR). C. difficile thrives in environments where antibiotic use is prevalent,disrupting the normal gut microbiome and allowing the bacterium to proliferate. The rise of hypervirulent strains and increasing resistance to antibiotics like metronidazole and vancomycin necessitate a multi-faceted approach to prevention and control. CDI prevention is paramount.

    Core Infection Control Practices: A Foundation for Reduction

    Robust infection control practices are the cornerstone of reducing HA-CDI. These aren’t simply guidelines; they require consistent implementation and monitoring.

    * Hand Hygiene: This remains the single most important intervention. alcohol-based hand rubs and thorough handwashing with soap and water are crucial, especially after contact with patients or their environment. Regular audits and feedback are essential to maintain compliance.

    * Environmental Cleaning & Disinfection: C. difficile spores are notoriously resilient.

    * Utilize sporicidal disinfectants (e.g., bleach, hydrogen peroxide vapor) for thorough cleaning of patient rooms, particularly high-touch surfaces.

    * Focus on bathrooms, bed rails, bedside tables, and medical equipment.

    * Implement a consistent cleaning schedule and monitor effectiveness through ATP testing or C. difficile environmental sampling.

    * Contact Precautions: Immediate implementation of contact precautions (gown and gloves) for patients with confirmed or suspected CDI is vital to prevent transmission. Dedicated equipment for CDI patients is also recommended.

    * Isolation Protocols: Single-patient rooms are ideal for CDI patients. When not feasible, cohorting patients with CDI can be considered, but requires strict adherence to infection control protocols.

    Antimicrobial Stewardship: Minimizing Selective pressure

    Judicious antibiotic use is critical in combating both CDI and AMR. Antimicrobial stewardship programs (ASPs) are essential.

    * Restrictive Antibiotic Policies: Implement policies that restrict the use of broad-spectrum antibiotics, particularly those frequently associated with CDI risk (e.g., fluoroquinolones, cephalosporins).

    * Prospective Audit and Feedback: ASPs should involve prospective review of antibiotic prescriptions, providing feedback to prescribers on appropriate use.

    * De-escalation Strategies: Encourage de-escalation of antibiotic therapy when culture results and clinical status allow.

    * Diagnostic Stewardship: Improve the accuracy and timeliness of diagnostic testing to avoid needless antibiotic use. Consider utilizing rapid diagnostic tests for CDI.

    Advanced Strategies & Emerging Technologies

    Beyond core practices, several advanced strategies show promise in reducing HA-CDI.

    * probiotic Use: While research is ongoing, certain probiotic strains may help restore gut microbiome balance and reduce CDI recurrence. Careful strain selection and governance protocols are crucial.

    * Fecal Microbiota Transplantation (FMT): FMT has demonstrated high success rates in treating recurrent CDI. Standardized protocols and donor screening are essential for safety.

    * Phage Therapy: Bacteriophages (viruses that infect bacteria) are being investigated as a potential alternative to antibiotics for CDI treatment.

    * Novel Disinfectants: Research continues into new disinfectants with improved sporicidal activity and reduced toxicity.

    * UV-C Disinfection: Utilizing ultraviolet-C (UV-C) light for room disinfection can supplement manual cleaning and further reduce spore burden.

    Diagnostic Advancements & Rapid Testing

    Timely and accurate diagnosis is crucial for effective management. Traditional laboratory methods can take 48-72 hours.

    * PCR Assays: Polymerase chain reaction (PCR) assays offer rapid detection of C. difficile toxin genes.

    * GDH/Toxin EIA Combination: Glutamate dehydrogenase (GDH) screening followed by toxin enzyme immunoassay (EIA) can improve diagnostic accuracy.

    * Point-of-Care Testing: Development of point-of-care CDI tests would allow for faster diagnosis and initiation of appropriate treatment.

    Surveillance & Data Analysis: Tracking Progress & Identifying Outbreaks

    Continuous surveillance is essential for monitoring CDI rates and identifying potential outbreaks.

    * Hospital-Wide Surveillance: Implement a system for tracking all suspected and confirmed CDI cases.

    * Molecular Typing: Utilize molecular typing methods (e.g., pulsed-field gel electrophoresis, whole-genome sequencing) to identify outbreaks and track the spread of specific strains.

    * Data Analysis & Reporting: Regularly analyze surveillance data to identify trends, risk factors, and areas for betterment.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    Identifying Probable Hantavirus Infections in Patients Clinically Suspected of Dengue: Insights from a Tertiary Care Hospital in Sri Lanka

    by Dr. Priya Deshmukh - Senior Editor, Health
    written by Dr. Priya Deshmukh - Senior Editor, Health

    “`html





    Hantavirus infections Mimicking Dengue Fever Raise Alarms in Sri Lanka

    Table of Contents

    Colombo, Sri Lanka – A recent study has revealed a meaningful overlap in symptoms between Hantavirus infection and Dengue fever, leading to potential misdiagnoses and delays in treatment. researchers are now focusing on improving diagnostic accuracy and raising awareness of this emerging public health concern. The findings underscore the need for broader testing protocols, particularly in regions where both diseases are prevalent.

    Diagnostic Challenges and Prevalence Rates

    The study, conducted among patients initially suspected of having Dengue fever, found that nearly 80% ultimately tested negative for the mosquito-borne illness. Though, a noteworthy 5.1% exhibited evidence of Hantavirus infection. This rate aligns with findings from neighboring countries such as Indonesia (4.23%) and Cambodia (4%), indicating a regional trend. The overlap in early symptoms-including fever, muscle aches, and fatigue-complicates accurate diagnosis.

    Testing and Detection Methods

    Researchers employed a combination of diagnostic techniques, including real-time RT-PCR to detect the virus’s genetic material and immunoblot assays to identify antibodies. While PCR tests were negative in all samples analyzed, IgM antibodies indicative of recent Hantavirus exposure were found in a subset of patients. This suggests that the virus may be present at low levels or during a phase where detection is challenging. It is also important to note that proper sample collection and handling are critical for accurate results.

    Demographic Trends and Risk Factors

    Interestingly,the study revealed that Hantavirus seropositivity was most common in individuals under the age of 10 and those over 61. This contrasts with typical patterns observed in other regions, where the disease primarily affects adults. However, studies in countries like Iran and Barbados have reported similar instances of pediatric cases, suggesting regional variations in disease presentation. Gender did not appear to be a significant factor in infection rates, with approximately 43% of cases occurring in males and 57% in females.

    clinical Severity and Outcomes

    the majority of Hantavirus-positive patients (76.2%) did not require intensive care, suggesting many infections are mild. However, two fatalities were recorded, resulting in a mortality rate of 9.5%. Common symptoms included fever, cough, muscle pain, and joint pain. In some cases,chest X-rays revealed pulmonary involvement,while others presented with renal failure,mirroring the symptoms of Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Pulmonary Syndrome (HPS). Supportive care remains the primary treatment approach, as specific antiviral therapies are currently limited.

    Comparative Prevalence Rates

    Region Hantavirus Prevalence (%)
    Sri Lanka (Current Study) 5.1
    Indonesia 4.23
    Cambodia 4.0

    Did You Know? Hantaviruses are typically transmitted to humans through contact with rodent droppings, urine, or saliva.

    Pro Tip: Practice good hygiene and rodent control measures in and around your home to minimize the risk of exposure to Hantaviruses.

    Accurate diagnosis remains a challenge due to overlapping symptoms with other febrile illnesses. Researchers are emphasizing the importance of considering Hantavirus infection in differential diagnoses, particularly in regions where it is endemic. This is crucial for prompt and appropriate medical intervention.

    What steps do you think public health officials should take to increase awareness of Hantavirus? how can we improve global surveillance for emerging infectious diseases like this one?

    Understanding Hantavirus and its Global Impact

    Hantaviruses are a family of viruses that can cause a range of illnesses in humans, from mild flu-like symptoms to severe and life-threatening conditions.These viruses are carried by rodents and transmitted to humans through various routes, including inhalation of airborne particles, direct contact with rodent excreta, or, less commonly, through rodent bites. The genus Hantavirus comprises over 35 different viruses, each associated with specific rodent hosts and geographic regions.

    Globally, Hantavirus infections are found in various parts of the world

    What specific epidemiological factors, beyond geographic location, should prompt consideration of hantavirus infection in a patient initially suspected of having dengue fever?

    Identifying Probable Hantavirus Infections in Patients Clinically Suspected of Dengue: Insights from a Tertiary Care Hospital in Sri Lanka

    Clinical Overlap: Dengue vs. Hantavirus

    In Sri Lanka, and across many tropical and subtropical regions, dengue fever is a significant public health concern. However, the initial clinical presentation of hantavirus pulmonary syndrome (HPS) and severe dengue can be remarkably similar, leading to diagnostic challenges. This overlap in symptoms – including fever,myalgia,headache,and even hemorrhagic manifestations – necessitates a heightened awareness and consideration of hantavirus infection in patients presenting with suspected dengue,particularly during periods of co-circulation.Misdiagnosis can delay appropriate management and significantly impact patient outcomes. Hantavirus disease frequently enough presents as a severe, rapidly progressive illness.

    Recognizing Key Differentiating Factors

    while symptom overlap exists, subtle clinical and epidemiological clues can point towards a hantavirus etiology. Hear’s a breakdown of key differentiators:

    * Geographic Exposure: While dengue is widespread in Sri Lanka,hantavirus is linked to specific rodent habitats. Patients reporting recent exposure to rodent-infested areas – particularly rural settings, agricultural lands, or abandoned buildings – should raise suspicion.

    * Respiratory Symptoms: Progressive shortness of breath and non-cardiac pulmonary edema are more characteristic of HPS than dengue. Dengue-related pleural effusions are less common and typically less severe.

    * Thrombocytopenia Pattern: Both diseases cause thrombocytopenia (low platelet count).However,the timing and severity can differ. HPS often presents with a more rapid and profound thrombocytopenia.

    * Renal Involvement: Acute kidney injury is frequently observed in HPS, often requiring dialysis. While dengue can cause renal impairment, it’s generally less severe.

    * Hemorrhagic Manifestations: While both can cause bleeding,the nature of the hemorrhage may differ. Petechiae and purpura are common in dengue, while larger ecchymoses and internal bleeding are more frequently seen in severe HPS cases.

    Diagnostic approaches: Beyond Dengue Serology

    Relying solely on dengue serological tests (NS1 antigen, IgM/IgG antibodies) can be misleading.A complete diagnostic workup is crucial when clinical suspicion for hantavirus exists.

    1. Detailed Patient History: Focus on potential rodent exposure – occupation (farmers, construction workers), recreational activities (hiking, camping), and home surroundings.
    2. Complete Blood Count (CBC): Monitor platelet count, white blood cell count (often leukopenia in HPS), and hematocrit.
    3. Renal function Tests: Assess creatinine, blood urea nitrogen (BUN), and electrolyte levels.
    4. Pulmonary Evaluation: Chest X-ray or CT scan to identify pulmonary edema.
    5. Hantavirus-specific Testing: This is the cornerstone of diagnosis.

    * RT-PCR: Detects hantavirus RNA in blood or urine samples during the acute phase of illness (first few days).

    * IgM/IgG Antibody Testing: Detects antibodies against hantaviruses. IgM antibodies typically appear within a few days of symptom onset, while igg antibodies develop later. Note: Availability of hantavirus-specific testing might potentially be limited in some regions, requiring referral to specialized laboratories.

    1. Differential Diagnosis: Rule out other potential causes of fever and respiratory distress, such as leptospirosis, influenza, and malaria.

    Rodent Control & Public Health Implications

    Effective rodent control is paramount in preventing hantavirus transmission. The CDC emphasizes this as the primary prevention strategy (https://www.cdc.gov/hantavirus/prevention/index.html).

    * Seal entry points: Close holes and cracks in homes and buildings.

    * Proper food storage: Store food in rodent-proof containers.

    * Safe cleaning practices: Moisten dust and debris before cleaning to avoid aerosolizing hantavirus particles. Wear a mask during cleaning.

    * Rodent trapping: Implement trapping programs in areas with high rodent populations.

    * public awareness campaigns: Educate the public about hantavirus risks and prevention measures.

    Case Study: A diagnostic Challenge

    In a recent case at our tertiary care hospital, a 35-year-old farmer presented with high fever, severe myalgia, and headache, initially diagnosed as probable dengue based on positive NS1 antigen testing.Though, the patient rapidly developed progressive dyspnea and acute kidney injury. Repeat investigations, prompted by the atypical clinical course, included hantavirus RT-PCR, which returned positive. The patient was subsequently managed with supportive care,including mechanical ventilation and renal replacement therapy,and eventually recovered.This case highlights the importance of considering hantavirus in the differential diagnosis of febrile illnesses, even in dengue-endemic areas.

    Benefits of Early and Accurate diagnosis

    * Improved Patient Outcomes: Prompt recognition and supportive care

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    Real-World Insights into Direct-Acting Antiviral Treatment Outcomes for Chronic Hepatitis C Across Various Genotypes in West Bengal, India

    by Dr. Priya Deshmukh - Senior Editor, Health
    written by Dr. Priya Deshmukh - Senior Editor, Health

    Demographic characteristics of the study population

    Table of Contents

    This study comprised 254 HCV sero-reactive individuals with 133 males (52.36%) and 121 females (47.63%). The age of the study population ranged from 20 to 83 years with a mean age of 51.91(± 11.82) years. The mean viral load of the RNA-positive individuals was 6.06(± 6.18) log IU/ml, and no significant difference in viral load was observed between genotype 3 and genotype 1.

    Occurrence of HCV viremia

    The frequency of active HCV infection in this study population was evaluated. Overall, HCV RNA positivity was 58.26%. HCV viremia was observed among 54.14% and 62.81% of males and females, respectively. The study found that HCV RNA positivity was highest (66.67%) in people aged 52 to 59. Blood transfusion, medical procedures, and improper use of syringes/needles were the common risk factors associated with active infection in the study, with blood transfusion accounting for the majority of patients (68.83%) (p < 0.05). Of the total 254 patients, 110 were cirrhotic and 144 non-cirrhotic. Among the cirrhotic patients, 69 (62.7%) were having decompensated cirrhosis. Decompensated cirrhosis of liver was associated with HCV viremia in 72.46% of cases (p < 0.05) (Table 1).

    Table 1 Tabular representation of HCV Viremia based on gender, age group, mode of transmission, and status of cirrhosis

    Genotype distribution among the study population

    Two HCV genotypes and seven subtypes were predominating in this study population (Fig- 1b). Of the 148 individuals that tested positive for HCV RNA, 120 (81%) had infection with genotype-3 (3a- 50%, 3b- 46.67%, 3 g- 2.5%, and 3i- 0.83%), while 28 (19%) had infection with genotype-1 (1a- 21.43%, 1b- 67.86%, and 1c- 10.71%). When the prevalence of HCV genotypes was compared across the seven age categories, those between the ages of 52 and 59 were most likely to have genotype 3 infection (82.22%, n = 37) (p < 0.05). Genotype distribution across gender, mode of transmission and status of cirrhosis is listed in Table 2.

    Table 2 Tabular representation of HCV genotype distribution based on gender, age group, mode of transmission, and status of cirrhosis

    Phylogenetic analysis of the study

    A phylogenetic tree was constructed with the representative sequences obtained from this study population (Supplementary Fig – 2) with reference sequences from the NCBI database. Corresponding representative sequences were found to cluster with the respective reference sequences.

    The phylogenetic tree was constructed by using MEGA X software package with 34 reference sequences downloaded from NCBI and 65 representative sequences from in-house sequencing. Prefix “NICED-VL/CLD” denoted in-house sequences.

    Assessment of DAA therapy

    This study monitored DAA therapy in 148 HCV RNA-positive individuals for 48 weeks. Of these 148 individuals, 120 individuals infected with genotype 3 were treated with Sofosbuvir (SOF) + Daclatasvir (DCV), and 28 individuals infected with genotype 1 were offered Sofosbuvir (SOF) + Ledipasvir (LDV)[[19, 20]. After 4 weeks of treatment, individuals were followed up for assessing the attainment of RVR, 8 patients (5.40%) (Male = 3, Female = 5) had lost follow-up within the first month of DAA treatment and the rest (n = 140) showed 100% RVR. During the 12-week follow-up, 15 patients (10.71%) (Male = 7, Female = 8) had lost follow-up. Out of the remaining 125 patients, 4 patients (3.2%) tested positive again, and remaining 121 patients showed EVR (96.8%). In the next follow-up visit, 112 patients (92.56%) showed SVR24while 9 patients (7.44%) tested RNA positive again. Hence, the SVR24 achievement rate was 92.56% (Fig 2).

    Fig. 2

    Schematic diagram of DAA treatment follow-up

    Out of 112 patients who achieved SVR2458 (51.78%) were male and 54(48.21%) were female. Gender-wise HCV genotype distribution of these 112 patients was gen-3a (42, 37.5%) (Female- 59.5% and male- 40.5%), gen-3b (50, 44.64%) (Female- 50% and male- 50%), gen-1a (2, 1.79%) (Male- 100%), gen-1b (15, 13.39%) (Female- 20% and male- 80%), and gen-1c (3, 2.68%) (Female- 33.33% and male- 66.67%) (Fig 3a) and among 13 relapse patients, 9 (69.24%) were male and 4 (30.76%) were female. Genotypically, these 13 relapse patients were distributed as follows- gen-3a (3, 23%) (Female- 33.3% and male- 66.7%), gen-3b (8, 62%) (Female- 37.5% and male- 62.5%), gen-1a (1, 7.69%) (Male- 100%), and gen 1b (1, 7.69%) (Male-100%) (Fig 3b).

    Fig. 3
    figure 3

    Comparative genotype distribution of HCV among patients based on treatment outcome; (a) Pie-donut chart representing the genotype distribution of the SVR24 achieved patients, (b) Pie-donut chart representing the genotype distribution of the patients who could not achieve SVR24

    Patients (n = 13) who failed to achieve SVR24 (relapsed) were re-interviewed and counseled again. A modified treatment regime with SOF + velpatasvir (VEL) + ribavirin (Riba) was prescribed to everyone re-interviewed for an additional 6 months. Of the 13 relapse patients taking SOF + VEL + Riba for another 24 weeks, 12 patients (92.3%) did not show active infection (considered as SVR’24 achieved), and in contrast, 1 patient (7.69%) continued to be nonresponsive to DAA. Overall, 99.2% of patients achieved either SVR24 or SVR’24. Patients who have achieved SVR24 were requested to revisit after 48 weeks for SVR48 evaluation. At the SVR48 assessment, only 65 patients (58.04%) attended, and upon evaluating the status of viremia, undetectable HCV RNA was found in all patients. Therefore, it can be inferred that among the attended patients the SVR48 achievement rate is 100%. Fig-2 represents the treatment follow-up for 48 weeks.

    Furthermore, Supplementary Fig-3 provides an overview of DAA efficacy by bifurcating the study population on the basis of the status of cirrhosis. Of the 77 SVR achieved patients, 57.14% were cirrhotic and 42.86% were non-cirrhotic, while out of 70 lost follow-up cases, 34.29% were cirrhotic and 65.71% were non-cirrhotic.

    Clinical assessment before and after DAA treatment

    Liver parameters were assessed for any significant changes between the baseline and post-treatment condition. We found that ALP, SGPT and Total Bilirubin returned to normal post-treatment. Significant differences (p < 0.001) were observed between two conditions in ALP, SGOT, SGPT, albumin, globulin and total bilirubin levels (Table 3).

    Table 3 Tabular representation of statistical comparison of clinical characteristics at baseline and 48 weeks after DAA treatment

    Liver related adverse events

    Among the 65 patients who completed 48 weeks of follow up, 37 were cirrhotic and 28 were non cirrhotic. Liver related adverse events were observed in 2 non-cirrhotic and 17 cirrhotic patients. Hepatomegaly and portal hypertension were the most common adverse effects. Cirrhotic patients had higher incidence of portal hypertension (13.5%) and hepatomegaly (13.5%). Occurrence of ascites (8.1%), hepatic encephalopathy (2.7%) and hepatocellular carcinoma (8.1%) were majorly observed in cirrhotic patients Table 4.

    Table 4 Liver associated adverse effects observed during the follow up

    ## Summary of “Acting Antiviral Treatment Outcomes for Chronic Hepatitis C Across Various Genotypes in West Bengal, India”

    Real-World Insights into Direct-Acting antiviral Treatment Outcomes for Chronic Hepatitis C Across Various Genotypes in West Bengal, India

    understanding Hepatitis C Prevalence in West Bengal

    West Bengal, India, carries a important burden of Hepatitis C Virus (HCV) infection. Factors contributing to this include historical intravenous drug use, inadequate sterilization practices in healthcare settings, and blood transfusions before widespread screening. Determining the prevalent HCV genotypes is crucial for effective treatment strategies. Common genotypes in the region include genotype 3, followed by genotypes 1 and 6. Accurate HCV genotype testing is the first step towards personalized treatment.

    The Revolution of Direct-Acting Antivirals (DAAs)

    The introduction of Direct-Acting Antivirals (DAAs) has dramatically altered the landscape of chronic Hepatitis C treatment.unlike older interferon-based therapies, DAAs offer:

    * High Sustained Virologic Response (SVR) rates: Typically exceeding 95% across most genotypes.

    * Shorter treatment durations: Usually 8-12 weeks, improving patient adherence.

    * Fewer side effects: Leading to better patient tolerance and quality of life.

    * Oral administration: Making treatment more convenient.

    commonly used DAAs include sofosbuvir, daclatasvir, ledipasvir, and velpatasvir, often used in combination regimens. The choice of regimen depends on the HCV genotype, presence of cirrhosis, and prior treatment history.

    Real-World Treatment Outcomes: A Genotype-Specific Analysis

    Analyzing treatment outcomes across different genotypes in West Bengal reveals nuanced patterns.

    Genotype 3: The Dominant Challenge

    Genotype 3 is the most prevalent in West Bengal. Studies show consistently high SVR rates (96-98%) with regimens like sofosbuvir/daclatasvir for 12 weeks. However, challenges remain:

    * Fibrosis Progression: A significant proportion of patients present with advanced fibrosis or cirrhosis at diagnosis, requiring careful monitoring.

    * Treatment Adherence: Socioeconomic factors can impact adherence, potentially lowering SVR rates.

    * Re-infection Risk: Individuals engaging in high-risk behaviors remain susceptible to re-infection.

    Genotype 1: Achieving High SVR with Optimized Regimens

    While less common than genotype 3, genotype 1 requires specific DAA combinations. Sofosbuvir/ledipasvir for 12 weeks demonstrates excellent efficacy (94-97%). Resistance-associated substitutions (RAS) are less frequent in genotype 1,simplifying treatment decisions.

    Genotype 6: Emerging Data and Treatment Strategies

    Genotype 6 is increasingly identified in West Bengal. Data on DAA efficacy for genotype 6 is still evolving, but preliminary results suggest that sofosbuvir-based regimens are generally effective. Ongoing research is crucial to refine treatment protocols.

    Factors Influencing Treatment Success Beyond Genotype

    Several factors beyond genotype impact HCV treatment outcomes:

    1. Liver Disease Severity: Patients with cirrhosis have lower SVR rates and a higher risk of complications.
    2. HIV co-infection: HIV/HCV co-infected individuals may require longer treatment durations or option regimens.
    3. diabetes and Metabolic Syndrome: These comorbidities can reduce treatment efficacy.
    4. Alcohol Consumption: Continued alcohol use negatively impacts treatment response.
    5. Drug Use: Active intravenous drug use increases the risk of re-infection.
    6. Treatment Adherence: Consistent medication intake is paramount for success.

    Addressing Barriers to Access and Affordability

    Despite the availability of DAAs,access remains a challenge for many in West bengal.

    * Cost of Treatment: While generic DAAs have reduced costs, they are still unaffordable for some patients. Government subsidies and charitable programs are vital.

    * Limited diagnostic Facilities: Access to HCV RNA testing and genotype testing is unevenly distributed.

    * Lack of Awareness: Many individuals are unaware of their HCV status and do not seek testing or treatment.

    * Stigma: Social stigma associated with HCV can deter individuals from seeking care.

    Monitoring and Post-Treatment Follow-Up

    Achieving SVR doesn’t guarantee complete resolution. Long-term monitoring is essential:

    * Surveillance for Hepatocellular Carcinoma (HCC): Patients with cirrhosis require regular HCC screening.

    * Assessment of Liver Fibrosis: Monitoring fibrosis progression or regression post-treatment.

    * Monitoring for Re-infection: Especially in individuals with ongoing risk factors.

    * Evaluation of Extrahepatic Manifestations: HCV can cause complications beyond the liver, requiring ongoing assessment.

    benefits of Successful HCV Treatment

    Successful HCV eradication offers significant benefits:

    * Reduced risk of cirrhosis and liver failure.

    * Decreased risk of HCC.

    * Improved liver function.

    * Enhanced quality of life.

    * Reduced transmission risk.

    Practical Tips for Healthcare Professionals

    * Prioritize HCV screening in high-risk populations.

    * Ensure accurate genotype testing before initiating treatment.

    * select appropriate DAA regimens based on genotype

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    Influenza & Aspergillosis: Iran ICU Insights

    by Dr. Priya Deshmukh - Senior Editor, Health
    written by Dr. Priya Deshmukh - Senior Editor, Health

    The Silent Threat: How Rising Invasive Aspergillosis Demands a New Era of Flu & Lung Disease Management

    A seemingly innocuous influenza infection can sometimes unlock a far more dangerous foe. Recent data reveals a concerning trend: a rise in invasive aspergillosis (IPA) – a serious fungal infection – even in non-ICU influenza patients. With a mortality rate of 30% in recent studies, and a growing understanding of risk factors beyond immunocompromise, the medical community faces a critical need to rethink prevention, diagnosis, and treatment strategies. This isn’t just about influenza; it’s about the complex interplay between respiratory viruses, underlying lung conditions, and a potentially deadly opportunistic infection.

    The Growing IPA Landscape: Beyond the ICU

    Historically, invasive aspergillosis was primarily associated with severely immunocompromised patients in intensive care units. However, a recent study analyzing 109 influenza patients revealed a 9.2% incidence of IPA among those hospitalized outside the ICU – a figure that demands attention. This finding is significant because it broadens the patient population considered at risk and highlights the potential for IPA to complicate even moderate influenza cases. The study also showed that patients with IPA were more likely to require ICU transfer and experienced longer hospital stays, underscoring the infection’s impact on healthcare resources.

    This trend aligns with observations from other research. A systematic review of over 6,000 severe IPA cases found a 10% incidence rate and a sobering 52% mortality rate. While our recent study reported a lower mortality of 30%, this may be attributable to the focus on a less critically ill patient cohort. The consistent identification of bacterial co-infections in IPA patients, as seen in our research and others, suggests a complex interplay between viral and bacterial pathogens that exacerbates the risk.

    Unmasking the Risk Factors: Who is Vulnerable?

    While immunocompromised individuals remain at heightened risk – with mortality rates reaching 14% versus 5% in ICU patients – the increasing incidence of IPA in non-immunocompromised individuals is particularly concerning. Several factors appear to contribute to this vulnerability. Underlying lung diseases, such as COPD, bronchiectasis, and a history of tuberculosis, are consistently identified as significant risk factors. These conditions create an environment of chronic inflammation and immune dysregulation, making the lungs more susceptible to fungal invasion.

    The COVID-19 pandemic may also be playing a role. Widespread corticosteroid use for treating severe COVID-19 is a known risk factor for IPA, and the lingering effects of the pandemic on lung health could be contributing to increased susceptibility. Exacerbations of COPD and bronchiectasis, driven by systemic inflammation, further amplify this risk.

    The Diagnostic Challenge: A Call for Rapid Detection

    Currently, diagnosing IPA relies heavily on invasive procedures like bronchoscopy and bronchoalveolar lavage (BAL) to obtain samples for culture and microscopic examination. While effective, these methods are time-consuming, resource-intensive, and carry inherent risks. The lack of a rapid, non-invasive diagnostic tool is a major obstacle to timely intervention and improved patient outcomes.

    Molecular methods for detecting influenza virus in BALF are available, but similar rapid molecular tests for Aspergillus species are still under development. The development and validation of such a test is a critical priority for improving IPA diagnosis and management.

    Future Trends & Proactive Strategies

    Looking ahead, several key areas require focused attention:

    1. Prophylactic Strategies: Preventing IPA in High-Risk Groups

    Given the potential severity of IPA, exploring prophylactic antifungal treatment for high-risk patients – particularly those with weakened immune systems or significant underlying lung disease – warrants further investigation. Prospective clinical trials are needed to assess the efficacy and safety of such strategies. This is especially crucial during peak influenza seasons.

    2. Enhanced Surveillance & Data Collection

    Improved surveillance systems are essential for accurately tracking the incidence and mortality of IPA. Standardized data collection protocols and national registries can help identify emerging trends and inform public health interventions. This includes better tracking of corticosteroid use and its correlation with IPA cases.

    3. Unraveling Host-Pathogen Interactions

    Further research is needed to understand the precise mechanisms by which influenza and other respiratory viruses predispose individuals to IPA. Bronchoscopic studies, as suggested by recent research, can help identify abnormal host-pathogen interactions and potential therapeutic targets. Understanding the role of the innate and adaptive immune response in controlling Aspergillus infection is also crucial.

    4. The Role of the Microbiome

    Emerging research suggests the gut microbiome plays a significant role in immune function and susceptibility to infection. Investigating the impact of the microbiome on IPA risk could open new avenues for prevention and treatment. Could modulating the gut microbiome offer a protective effect against fungal invasion?

    Frequently Asked Questions

    What is Invasive Aspergillosis (IPA)?

    IPA is a serious fungal infection caused by Aspergillus molds. It typically affects the lungs but can spread to other organs. It’s particularly dangerous for individuals with weakened immune systems or underlying lung disease.

    How is IPA diagnosed?

    Diagnosis usually involves bronchoscopy and bronchoalveolar lavage to obtain samples for culture and microscopic examination. However, there’s a pressing need for faster, non-invasive diagnostic tests.

    Who is at risk of developing IPA?

    Individuals with weakened immune systems, underlying lung diseases (COPD, bronchiectasis, tuberculosis), and those who have recently received corticosteroids are at increased risk. Recent influenza infection also appears to be a significant risk factor.

    Is IPA preventable?

    While not always preventable, vaccination against influenza and proactive management of underlying lung conditions can reduce risk. Research is ongoing to explore the potential of prophylactic antifungal treatment for high-risk individuals.

    The rising incidence of IPA represents a significant challenge to public health. By prioritizing research, improving diagnostic capabilities, and implementing proactive prevention strategies, we can mitigate this silent threat and protect vulnerable populations from this potentially deadly infection. What steps will healthcare systems take to address this growing concern?

    Explore more insights on managing respiratory infections in our comprehensive guide.

    0 comments
    0 FacebookTwitterPinterestEmail
    Newer Posts
    Older Posts
    @2025 - All Right Reserved.

    Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
    [email protected]

    Adblock Detected

    Please support us by disabling your AdBlocker extension from your browsers for our website.